PLA2R1 and atherosclerosis: So, does podocyte injury caused by anti-PLA2R antibody cause increased IL-6 production by podocytes, which in turn promotes atherosclerosis and thrombosis, thus increasing the risk of cardiovascular, cerebrovascular, and thromboembolic events in patients with pMN?